Open access target validation is a more efficient way to accelerate drug discovery.
There is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-06-01
|
| Series: | PLoS Biology |
| Online Access: | http://europepmc.org/articles/PMC4456377?pdf=render |
| id |
doaj-8460a6c8e6bb46f187474e5dc3c4e203 |
|---|---|
| record_format |
Article |
| spelling |
doaj-8460a6c8e6bb46f187474e5dc3c4e2032021-07-02T10:29:02ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852015-06-01136e100216410.1371/journal.pbio.1002164Open access target validation is a more efficient way to accelerate drug discovery.Wen Hwa LeeThere is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how an open model of precompetitive public-private research partnership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient and disease foundations.http://europepmc.org/articles/PMC4456377?pdf=render |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Wen Hwa Lee |
| spellingShingle |
Wen Hwa Lee Open access target validation is a more efficient way to accelerate drug discovery. PLoS Biology |
| author_facet |
Wen Hwa Lee |
| author_sort |
Wen Hwa Lee |
| title |
Open access target validation is a more efficient way to accelerate drug discovery. |
| title_short |
Open access target validation is a more efficient way to accelerate drug discovery. |
| title_full |
Open access target validation is a more efficient way to accelerate drug discovery. |
| title_fullStr |
Open access target validation is a more efficient way to accelerate drug discovery. |
| title_full_unstemmed |
Open access target validation is a more efficient way to accelerate drug discovery. |
| title_sort |
open access target validation is a more efficient way to accelerate drug discovery. |
| publisher |
Public Library of Science (PLoS) |
| series |
PLoS Biology |
| issn |
1544-9173 1545-7885 |
| publishDate |
2015-06-01 |
| description |
There is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how an open model of precompetitive public-private research partnership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient and disease foundations. |
| url |
http://europepmc.org/articles/PMC4456377?pdf=render |
| work_keys_str_mv |
AT wenhwalee openaccesstargetvalidationisamoreefficientwaytoacceleratedrugdiscovery |
| _version_ |
1721332013647003648 |